Condition: Meningioma · Sponsor: University Hospital Heidelberg
While surgical resection remains the primary treatment approach for symptomatic or growing meningiomas, radiotherapy represents an auspicious alternative in patients with meningiomas not safely amenable to surgery. Biopsies are often omitted in light of potential postoperative neurological deficits, resulting in a lack of histological grading and (molecular) risk stratification. In this prospective explorative biomarker study, extracellular vesicles in the bloodstream will be investigated in patients with macroscopic meningiomas to identify a biomarker for molecular risk stratification and disease monitoring.
This description comes directly from the study's public registry record.
Max Deng, MD · +496221 56 · maximilian.deng@med.uni-heidelberg.de
Adriane Lentz-Hommertgen, PhD · +496221 56 · adriane.lentz-hommertgen@med.uni-heidelberg.de
Always discuss trial participation with your own doctor first.
| University Hospital of Heidelberg, Radiation Oncology | Heidelberg, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06104930